Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a new drug combo wipe out three parasitic diseases at once?

NCT ID NCT07159373

Disease control Sponsor: Medicines Development for Global Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This large study in Fiji tests whether a new combination of drugs (moxidectin plus two others) can safely treat three common parasitic infections: lymphatic filariasis, scabies, and strongyloidiasis. About 5,100 people will receive either the new combo or the standard treatment once a year for three years. The goal is to see if the new combo clears the infections better and with similar side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
moxidectin (combined with diethylcarbamazine and albendazole)
What this could lead to
If successful, this could provide a safer or more effective way to control and eventually eliminate these parasitic diseases in affected communities.
What could go wrong
This is a large Phase 3 trial, but results may not apply to all regions. Side effects are possible, and the treatment may not work better than the existing option.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 5,100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Provision of signed and dated informed consent. 2. Resident in one of the study locations. Exclusion Criteria: There are no exclusion criteria to participation in the study. Treatment Exclusion Criteria: Participants are ineligible to receive the treatment regimen allocated to their village if they meet any of the following criteria: 1. Severe illness (any illness that is severe enough to interfere with activities of daily living); 2. Known or suspected allergy to ivermectin, moxidectin, diethylcarbamazine or albendazole; 3. Pregnant; 4. Breastfeeding a baby within 7 days of birth; 5. Age \< 4 years for villages randomised to moxidectin, diethylcarbamazine, and albendazole (MoxDA); or 6. Age \< 2 years or weight \< 15 kg for villages randomized to ivermectin, diethylcarbamazine and albendazole (IDA).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lymphatic filariasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

filarial elephantiasis filariasis scabies strongyloidiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphatic filariasis Scabies Strongyloidiasis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ministry of Health and Medical Services Fiji

    Suva, Fiji

More trials for these conditions

Other studies related to the condition(s) this trial covers.